Research progress of chimeric antigen receptor natural killer cells in hematological malignancies
10.3760/cma.j.cn121382-20200824-00114
- VernacularTitle:嵌合抗原受体自然杀伤细胞在血液系统恶性肿瘤中的研究进展
- Author:
Rui CUI
;
Qi DENG
- From:
International Journal of Biomedical Engineering
2021;44(1):77-82
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor natural killer cell (CAR-NK) is a new promising immunotherapy. NK cell can derive from peripheral blood cells, cord blood cells, NK-92 cell line and iPSC cells. CAR-NK cells can recognize target antigens non-specifically and are not restricted by human leukocyte antigens. Allogeneic infusion of CAR-NK cells does not cause graft-versus-host disease. It has a strong effect on primary cells of leukemia, lymphoma and multiple myeloma, thus making animal models have strong anti-tumor effect. Therefore, as a "off-the-shelf" product, CAR-NK cells have a wide range of clinical applications. In this paper, the construction of CAR-NK vector and its preliminary clinical application in hematological tumors and the challenges were reviewed.
